Home

Pfizer (PFE)

24.48
+0.18 (0.74%)
NYSE · Last Trade: Jun 11th, 7:21 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close24.30
Open24.33
Bid24.35
Ask24.42
Day's Range24.32 - 24.69
52 Week Range20.92 - 31.54
Volume38,552,922
Market Cap137.25B
PE Ratio (TTM)17.74
EPS (TTM)1.4
Dividend & Yield1.720 (7.03%)
1 Month Average Volume41,217,803

Chart

About Pfizer (PFE)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More

News & Press Releases

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Via FinancialNewsMedia · June 11, 2025
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Offfool.com
Steady growth and dividend increases over decades can make investors remarkably wealthy.
Via The Motley Fool · June 11, 2025
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates there will be over 35 million new cancer cases by 2050, a massive 77% increase from the estimated 20 million cases in 2022. This rising occurrence of cancer has been attributed to lifestyle changes in an increasingly geriatric population in both developed countries and emerging economies. Environmental factors such as pollution and the high penetration of microplastics, a potential carcinogen, are also contributing to the growing number of cancer cases. As the global burden of cancer continues to go up, government and private organizations are increasing funding in both healthcare infrastructure and investment into research and development of therapeutics and potential cures for various kinds of cancers. Many federal early detection programs have been launched with large players in the pharmaceutical sector looking to increase the number of clinical trials and drug discovery studies undertaken. These innovations are propelling market expansion, with the sector expected to witness significant growth in the coming years as new technologies and therapies continue to emerge. A new research report from BioSpace, said the global oncology market size was USD 321.19 billion in 2024, and calculated at USD 356.20 billion in 2025 is expected to reach around USD 903.81 billion by 2034, growing at a CAGR of 10.9% for the forecasted period. the development of the global healthcare infrastructure and cancer continuing to be one of the leading causes of death worldwide drives growth in the global oncology market. Active oncology biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), BioNTech SE (NASDAQ: BNTX), Arvinas, Inc. (NASDAQ: ARVN), Pfizer Inc. (NYSE: PFE).
By FN Media Group LLC · Via GlobeNewswire · June 11, 2025
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidiainvestors.com
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.
Via Investor's Business Daily · June 10, 2025
2 Weight Loss Drug Stocks That Are Screaming Buys in Junefool.com
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.
Via The Motley Fool · June 10, 2025
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Tradingbenzinga.com
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
Via Benzinga · June 10, 2025
Vaccine Stocks Alert: Has RFK Jr.'s CDC Panel Shakeup Sent Retail Traders To The Sidelines?stocktwits.com
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."
Via Stocktwits · June 10, 2025
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.investors.com
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.
Via Investor's Business Daily · June 9, 2025
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodesstocktwits.com
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.
Via Stocktwits · June 9, 2025
These S&P500 stocks are the most active in today's sessionchartmill.com
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Via Chartmill · June 9, 2025
Pfizer CEO Reportedly Says Company Made No Drug Price Pledges In Meeting With Trump Administration: Retail Sentiment Improvesstocktwits.com
The meeting follows an executive order from President Trump last month, which directed drugmakers to lower medicine prices to the levels paid by other high-income countries.
Via Stocktwits · June 9, 2025
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yieldsbenzinga.com
Via Benzinga · June 9, 2025
3 Stocks With Mouthwatering Dividends You Can Buy Right Nowfool.com
Via The Motley Fool · June 8, 2025
Should You Buy Pfizer Stock Right Now?fool.com
Via The Motley Fool · June 7, 2025
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approvalbenzinga.com
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients
Via Benzinga · June 6, 2025
RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Expertsbenzinga.com
U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.
Via Benzinga · June 6, 2025
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –
By Arvinas Inc. · Via GlobeNewswire · June 6, 2025
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologisfool.com
Via The Motley Fool · June 5, 2025
Here Are All 6 Stocks I've Bought Through 5 Months of 2025fool.com
A volatile stock market represents an ideal opportunity for long-term investors to pounce.
Via The Motley Fool · June 5, 2025
Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors
American pharmaceutical and biotech company Pfizer has been sued by hundreds of American and UK women after a recent study revealed that a contraceptive injection developed by the company increased their risk of developing brain tumors significantly. Four hundred American women have already filed the lawsuit in a Florida county, and around 200 women from the UK are also considering suing the pharmaceutical firm, the Daily Mail reports.
Via Investor Brand Network · June 4, 2025
S&P 500 Earnings Stun The Street In Q1 With Broad-Based Beats, Double-Digit Growthbenzinga.com
Nearly 80% of S&P 500 firms beat Q1 earnings forecasts. Profit growth hit 13.3%, led by tech and health care, says FactSet.
Via Benzinga · June 3, 2025
These 2 Dow Stocks Are Set to Soar in 2025 and Beyondfool.com
Apple and Cisco could generate surprising gains over the next few years.
Via The Motley Fool · June 3, 2025
3 Safe Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 11.35% -- That Make for No-Brainer Buys in Junefool.com
Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.
Via The Motley Fool · June 3, 2025
Why BioNTech Stock Soared Todayfool.com
Bristol Myers Squibb just agreed to shower BioNTech with cash.
Via The Motley Fool · June 2, 2025
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time.
By Pfizer Inc. · Via Business Wire · June 2, 2025